Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Chinook Launches to Tackle Kidney Disease

British Columbia-based Chinook Therapeutics burst onto the scene with $65 million in hand and a goal of driving a portfolio of compounds aimed at kidney diseases into the clinic by 2021.

Read More »

Havas Health & You Launches Havas ECS

Havas Health & You introduced Havas ECS, a specialized strategic communications advisory and education company focused on the importance and value of foundational scientific knowledge on the endocannabinoid system,

Read More »

Nektar Forms New Subsidiary

With an opioid molecule awaiting regulatory review, Nektar Therapeutics announced the launch of Inheris Biopharma, which will be responsible for the commercialization of NKTR-181.

Read More »

ElevateBio Launches with $150 Million Aimed at Growing Cell and Gene Therapy Companies

ElevateBio, a new company focused on the development of startup cell and gene therapy companies, launched with a $150 million Series A financing round.

Read More »

Alphabet’s GV leads funding in gene editing company Verve Therapeutics

Alphabet’s venture capital arm GV led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.

Read More »

UK-Based Accelerator Start Codon Launches with Investment from Genentech and Others

Start Codon launched in Cambridge, England with funding from keystone investors including Cambridge Innovation Capital, Babraham Bioscience Technologies, Genentech, Jonathan Milner and Ian Tomlinson.

Read More »

Roivant and Sinovant Launch Cytovant

Vivek Ramaswamy’s Roivant Sciences has launched another “vant” company, this time in China, in a partnership with Hong Kong-based Sinovant Sciences.

Read More »

Glenmark Adds 400 Employees, Spins off Innovation Business

Mumbai-based Glenmark Pharmaceuticals is spinning off its innovation business into a U.S.-based standalone company.

Read More »

With 5 Gene Therapies Licensed From Penn, Passage Bio Launches With $115.5 Million Series A

Philadelphia-based Passage Bio launched with a Series A financing round valued at $115.5 million, led by OrbiMed Advisors.

Read More »

Axovant Announces Formation of Arvelle Therapeutics

Axovant Sciences, a clinical-stage company developing innovative gene therapies, today announced the formation of Arvelle Therapeutics and the strategic transition of its legacy small molecule team into the newly formed company.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom